Spinal cord injury

Rosies Base signs research agreement with SpineCraft for Next-Generation Spinal Implants

Retrieved on: 
Wednesday, October 19, 2022
Other Health, Research, General Health, Machine Tools, Metalworking & Metallurgy, Medical Devices, Other Manufacturing, Steel, Science, Surgery, Manufacturing, Other Science, Health, Quality of life, Biofilm, Nano, Spinal cord injury, COO, Patient, Research, Partnership, Technology, Marketing, MD, Alloy, Cervical spine disorder, Sintering, Bookbinding

The agreement with SpineCraft calls for the companies to investigate the compatibility and effectiveness of nanoTi in the manufacture of spinal implant rods.

Key Points: 
  • The agreement with SpineCraft calls for the companies to investigate the compatibility and effectiveness of nanoTi in the manufacture of spinal implant rods.
  • Nano-structured metals offer a variety of advantages over conventionally produced alloys, including higher strength, improved processing capabilities, and novel biological properties, said Fumie Yusa, Ph.D., vice president and COO of Rosies Base.
  • We expect our partnership with SpineCraft, a leader in the spinal orthopedics field, to demonstrate the superiority of our nanoTi alloy compared with conventional medical-grade titanium.
  • We are eager to explore the potential of the innovative nanoTi alloy developed by Rosies Base.

Fasano Longevity Conference to Cover Politics, Medical Research and Investments

Retrieved on: 
Tuesday, October 18, 2022
Legal, Insurance, Human Resources, Finance, Consulting, Banking, Accounting, Professional Services, Small Business, Other Professional Services, Transfer, Structured settlement, Use, Augustus A. Bird, Life, Growth, Conference, Partner, Natural experiment, Research, South African National Editors' Forum, University, The Cook Political Report, Word Association, Longevity, Health, Fasano, Life expectancy, CEO, Spinal cord injury, Artificial intelligence, Cook, Paralysis, Pharmaceutical industry, Medical device, Financial services

The Fasano Longevity Conference, which will be held on November 7th, will include a wide range of topics bearing on longevity markets.

Key Points: 
  • The Fasano Longevity Conference, which will be held on November 7th, will include a wide range of topics bearing on longevity markets.
  • Said Michael Fasano, "This year's Conference covers life settlement, structured settlement and risk transfer markets while also presenting some groundbreaking medical research and timely political insights."
  • The Fasano Conference is a time efficient, one-day event that covers the most current and relevant topics affecting the longevity markets and has been favored by the investment and financial community.
  • Fasano Associates is a leading underwriting consulting firm serving the life, health, annuity and life settlement markets.

InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, October 11, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Medical Devices, Clinical Trials, U.S. Securities and Exchange Commission, Securities Act of 1933, Sale, SEC filing, SEC, Therapy, Hospital, PAETEC Holding Corp., Invivo Wines, LLC, Park Avenue, Research, Security (finance), Massachusetts General Hospital, Company, Marketing, Form, Spinal cord injury, Prospectus, Massachusetts Institute of Technology, 3rd Floor, Boston, Technology, Nasdaq

The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the registered direct offering.

Key Points: 
  • The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the registered direct offering.
  • The combined purchase price for one share of common stock or pre-funded warrant and the associated preferred investment option was $5.25.
  • The gross proceeds to the Company from the offerings were approximately $9.0 million, before deducting placement agent fees and other offering expenses payable by the company.
  • InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

Retrieved on: 
Monday, October 10, 2022
Biotechnology, Genetics, Health, Clinical Trials, IND, European Patent Office, Injury, Program, SCI, Patent, EPO, Infection, Compte rendu, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TASE, Cancer, Company, United States Patent and Trademark Office, IP, VAC2, FDA, Large-cell lung carcinoma, Hoffmann-La Roche, Intention, Degenerative disease, Lineage Cell Therapeutics, Annual report, Roche, California Institute for Regenerative Medicine, Cell, Security (finance), Priority right, U.S. Securities and Exchange Commission, USPTO, Spinal cord injury, Ageing, OPC, Disease, SEC, Spinal cord, Geographic atrophy, Patient, Orphan drug, NYSE American, Food, Â, Retinal, Disability, Forward-looking statement, Severe cognitive impairment, Auditory neuropathy, Regenerative medicine, European Patent Convention, Pharmaceutical industry, Genentech

16/750,975, entitled Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells, with claims covering proprietary manufacturing processes developed by Lineage for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury (SCI).

Key Points: 
  • 16/750,975, entitled Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells, with claims covering proprietary manufacturing processes developed by Lineage for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury (SCI).
  • These new patents highlight our ability to generate differentiated cell types from undifferentiated pluripotent cells and are valuable outputs from our platform.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.
  • Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 10, 2022
Health, Pharmaceutical, Stem cell, CDC, Government, PD, Review, B cell, VPS, National, Degenerative disease, Parkinson's disease, Research, GBP, MEA, Primary, Cancer, Temperature, Stockholm Environment Institute US Center, Chronic condition, Medical Research Future Fund, Industry, MRFF, CVD, Diabetes, Equipment, Spinal cord injury, Innovation, Osteoarthritis, Chief executive officer, USD, Patient, Pharmaceutical industry, Technology, Software

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets.

Key Points: 
  • Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets.
  • The global cell therapy market is segmented based on Use-type, Therapy Type, Product, Technology, Application, and Region.
  • Based on Technology it is categorized into Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, and Three-Dimensional Technology.
  • In November 2019, the Australian government released The Stem Cell Therapies Mission, a 10-year strategy for stem cell research in Australia.

Allsup Employment Services Joins United Spinal Association In Oct. 18 National Disability Employment Awareness Month Event

Retrieved on: 
Friday, October 7, 2022
Insurance, Air Carrier Access Act, Veteran, Disability, City, Social Security, Ticket to Work, National Disability Employment Awareness Month, State Employment Service (Azerbaijan), SSA, Employment, Health, First Time, American Veterans Disabled for Life Memorial, Workforce, Allsup, Social, Medicare, Americans with Disabilities Act of 1990, Association, CVS Health, SCI/D, GLOBE, Spinal cord injury, PDF, Health insurance, United Spinal Association

Belleville, Illinois, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Allsup Employment Services , which provides return to work services through the Social Security Administrations (SSA) Ticket to Work program, will join with United Spinal Association to support National Disability Employment Awareness Month (NDEAM) in October 2022.

Key Points: 
  • Belleville, Illinois, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Allsup Employment Services , which provides return to work services through the Social Security Administrations (SSA) Ticket to Work program, will join with United Spinal Association to support National Disability Employment Awareness Month (NDEAM) in October 2022.
  • ET featuring Diane Winiarski, director of Allsup Employment Services, and three additional panelists:
    Joshua Basile: United Spinal Association board secretary and trial attorney.
  • Jos Hernandez: Community organizer for the Consumer Directed Personal Assistance Association of New York State (CDPAANYS) and president of United Spinals New York City chapter.
  • Allsup Employment Services understands how beneficial it is for people with disabilities to return to work if they are medically able to do so.

InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Friday, October 7, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Hospitals, Clinical Trials, U.S. Securities and Exchange Commission, Securities Act of 1933, Sale, SEC filing, SEC, Therapy, Hospital, PAETEC Holding Corp., Invivo Wines, LLC, Park Avenue, Research, Security (finance), Massachusetts General Hospital, Company, Marketing, Form, Spinal cord injury, Prospectus, Massachusetts Institute of Technology, 3rd Floor, Boston, Pharmaceutical industry, Technology, Nasdaq

Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or pre-funded warrants in lieu thereof) in a private placement priced at-the-market under Nasdaq rules.

Key Points: 
  • Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or pre-funded warrants in lieu thereof) in a private placement priced at-the-market under Nasdaq rules.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
  • The gross proceeds to the company from the offerings are expected to be approximately $9.0 million, before deducting placement agent fees and other offering expenses payable by the company.
  • InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

Encompass Health and Piedmont announce plans to build a 40-bed inpatient rehabilitation hospital in Athens, Georgia

Retrieved on: 
Wednesday, October 5, 2022
Quality of life, Disease, Fortune, SEC, Growth, Patient, Forbes, Organization, Newsroom, NYSE, Hospital, Nursing care plan, Twitter, Instagram, Encompass Health, Grammy Award for Best Large Jazz Ensemble Album, Lists of diseases, Partnership, Company, Medicare, Stroke, Amputation, Brain, Safety, Patient safety organization, Encompass, Injury, Environment, Spinal cord injury, EHC, Pharmacy, Health insurance, Health care, Facebook

BIRMINGHAM, Ala. and ATHENS, Ga., Oct. 5, 2022 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) and Piedmont today announced they have been awarded a certificate of need to build a freestanding, 40-bed inpatient rehabilitation hospital in Athens, Georgia.

Key Points: 
  • BIRMINGHAM, Ala. and ATHENS, Ga., Oct. 5, 2022 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) and Piedmont today announced they have been awarded a certificate of need to build a freestanding, 40-bed inpatient rehabilitation hospital in Athens, Georgia.
  • Encompass Health currently has five inpatient rehabilitation hospitals in Georgia and has announced plans to open an additional two hospitals in the state over the next three years, including Atlanta and Columbus.
  • This includes 22 hospitals, including three inpatient rehabilitation hospitals, 65 Piedmont Urgent Care centers, 25 QuickCare locations, 1,875 Piedmont Clinic physician practices and more than 3,000 Piedmont Clinic members.
  • Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States.

ONWARD Announces Topline Results from the LIFT Home Study Supporting Safety and Feasibility of ARC-EX Therapy to Treat People with Spinal Cord Injury at Home

Retrieved on: 
Wednesday, October 5, 2022
Research, Medical Devices, Finance, Professional Services, Other Health, Biotechnology, Physical Therapy, General Health, Health, Science, Quality of life, Incontinence, Euronext, Movement, Spinal cord, PT, Infection, Science, U.S. FDA, Patient, Loss of Sensation, High Tech Campus Eindhoven, NCS, Technology, University, Company, SCI, Health, CEO, Nature, Afghanistan Research and Evaluation Unit, DPT, Safety, Evaluation, Spinal cord injury, Forward-looking statement, University of Minnesota, ARC, Paralysis, University of Washington Department of Bioengineering, Pharmaceutical industry, Risk management, Medical device, Research, Shepherd Center

ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with spinal cord injury (SCI) and other movement disabilities.

Key Points: 
  • ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with spinal cord injury (SCI) and other movement disabilities.
  • The main objective of the study is to evaluate the safety and feasibility of ARC-EX Therapy when used at home.
  • The absence of any device-related adverse events confirmed the favorable safety results observed during the Up-LIFT Study when ARC-EX Therapy was used in clinics.
  • Approximately 7 million people globally have a spinal cord injury, with over 650,000 in the U.S. and Europe alone.

'Military Makeover with Montel' Selects Thomas Family from Indian Land, SC for its Next Home Makeover

Retrieved on: 
Tuesday, October 4, 2022
American Forces Network, Cancer, Government, Marketing, Spinal cord injury, Courage, Disability, Bronze Star Medal, AC, Life, Navy, Department, CEO, Defense, SC, Lifetime, Injury, Multimedia, Family, Marines, History of the United States Army National Guard, Organic, Hope, Veteran, Army National Guard, Makeover, Department of Defence, Woman, United States Navy, Desegregation in the United States Marine Corps, Montel, Interior design

CHARLOTTE, S.C., Oct. 4, 2022 /PRNewswire/ -- 'Military Makeover with Montel,' A BrandStar Original show, is honored to present Purple Heart Veteran Jonathan Thomas and his family with a home makeover on the new, upcoming season in Indian Land, SC.

Key Points: 
  • After being deployed twice to Iraq and Afghanistan, Thomas was blown out of a guard tower by a suicide bomber.
  • A few years later, Thomas met his soon to be wife, Natasha and they had four children together.
  • In 2012, Thomas became an instructor at Fort Benning, GA. During this time, he was diagnosed with cancer, subsequently ending his sixteen-year military career.
  • The Thomas family currently resides in South Carolina and is involved with several charities, including Bended Knee Outdoors, a charity that helps children with disabilities.